INTRODUCTION
Neisseria meningitidis infection continues to cause considerable disability and mortality throughout the world. Although polysaccharide conjugate vaccines have been developed and used successfully against many of the serogroups of N. meningitidis, such a strategy has proved ineffective against group B meningococci. This serogroup now represents the majority of cases in the UK (Gray et al., 2006) . Vaccines containing outer membrane vesicle (OMV) preparations have been used to vaccinate successfully against specific outbreak strains of serogroup B N. meningitidis Oster et al., 2007; Rodríguez et al., 1999) , but such preparations do not give sufficient cross-protection to justify their use as universal meningococcal vaccines. Protein antigens that are protective against serogroup B meningococci have been identified by reverse vaccinology (Giuliani et al., 2006) and incorporated into the 4CMenB vaccine (Serruto et al., 2012) . However, even this does not provide universal protection against serogroup B strains; meningococcal antigen typing system results predicted that only 73 % of UK B strains would be killed by postvaccination sera (Vogel et al., 2013) . There is therefore a continuing need to characterize the immune response to neisserial infection and to identify further vaccine candidates that might provide a cross-protective vaccine.
Classic studies performed in the 1960s demonstrated the importance of bactericidal antibody for protection against meningococcal disease, as reviewed by Pollard & Frasch (2001) . Several lines of evidence suggested that important and pan-reactive determinants of immunity remain to be discovered. (i) In immunocompetent individuals, a single episode of meningococcaemia conferred permanent immunity to all types of meningococci (Pollard & Frasch, 2001; Goldschneider et al., 1969a; Goldschneider et al., 1969b lactamica provided immunity to meningococcal disease (Pollard & Frasch, 2001; Goldschneider et al., 1969a; Goldschneider et al., 1969b) . (iii) Inoculation of mice with attenuated mutant meningococcal strains induced crossreactive immune responses (Li et al., 2004; Newcombe et al., 2004) . Collectively, these findings indicated that natural exposure (to either N. meningitidis or N. lactamica) can provide long-term, cross-reactive protection; however, the identity of the antigens involved remains unknown.
The individuals chosen for this study had no recorded incidence of meningococcal infection therefore any antibodies detected would have arisen from carriage of the meningococcus or cross-reactive bacterial strains. There are many different meningococcal disease strains in circulation, and those isolated from healthy carriers similarly fall into many different electrophoretic types (ETs) and sequence types (STs) (Comanducci et al., 2002) . In a long-term study of university students (Ala'Aldeen et al., 2000) , it was observed that carriage can be persistent with the same or different strains. Also, some non-carriers were observed to become carriers, but some individuals were persistent non-carriers. Evidence of carriage does not appear to preclude colonization or invasion by a heterologous or homologous strain (Ala'Aldeen et al., 2000) .
The proteome of both the serogroup B strain, MC58 (Mignogna et al., 2005) , and the serogroup A strain, Z4970 (Bernardini et al., 2004) , as well as the composition of OMV preparations from both N. meningitidis MC58 and NZ98/54 (Abel et al., 2007; Uli et al., 2006; Vaughan et al., 2006; Vipond et al., 2006) and N. lactamica Y92-1009 (Abel et al., 2007; Vaughan et al., 2006) have been catalogued using a combination of 2D SDS-PAGE and MS (Wheeler et al., 2007) . Western blotting has provided information on the immunogenicity of the meningococcal proteins (Mendum et al., 2009; Williams et al., 2009) . This immunoproteomics approach has been applied to a wide range of organisms, including Mycobacteria tuberculosis (Sinha et al., 2002) , Streptococcus pneumonia (Ling et al., 2004) , Staphylococcus epidermidis (Sellman et al., 2005) and Candida albicans (Fernández-Arenas et al., 2004) , and in many cases has led to the identification of novel antigens that have been demonstrated to be protective in animal models (Fernández-Arenas et al., 2004; Ling et al., 2004; Sellman et al., 2005) . These studies all measure the immunogenicity of proteins in a cellular lysate. However, a potential weakness, at least for finding antigens relevant to protection, is that these methods detect immune responses to many cytoplasmic proteins. It is likely that these responses are generated to proteins released from dead cells during the infection process and are thereby unlikely to be targets of protective immunity (Mendum et al., 2009) . In this study, we utilized an alternative approach whereby we identified only antigens exposed on the surface of live intact bacterial cells by immunoprecipitation with sera from healthy subjects [cell surface immunoprecipitation (CSIP)] followed by protein identification by liquid chromatography-tandem MS (CSIP-MS). We confirm that several of the antigenic targets are indeed surface exposed and many were previously characterized vaccine candidate antigens. Each donor gave a unique CSIP-MS profile, indicating that natural immunity may recognize a very heterogeneous set of target antigens. This novel immunoproteomics approach is a powerful method capable of dissecting the protective immune response to infectious agents such as the meningococcus.
METHODS
Bacteria strains and media. N. meningitidis L91543 (obtained from the Manchester Public Health Laboratory) serogroup C:2a:P1.2, ST-11; ET-37 strain and MC58 serogroup B:15:P1.7,16, ST-74; ET-5 strain (Public Health England). Cultures were grown on Columbia Agar Base supplemented with 6 % horse blood (CAB) at 35 uC with 5 % CO 2 .
Serum samples. Healthy venous blood from volunteers, with no history of meningococcal disease, was collected from 10 adult subjects (eight females, two males, aged 25-50 years), with no pre-selection, into BD CAT vacutainers. Once clotted, the serum was removed and stored in aliquots at 220 uC. We also used a commercial pooled human serum; age or sex was not specified (Sigma). All serum samples were heat inactivated at 56 uC for 30 min prior to use to inactivate the complement, and so prevent killing and cell lysis. Consent from all donors was obtained. Collection and use of human serum was approved by the University of Surrey Ethics Committee.
CSIP. N. meningitidis L91543 and MC58 were grown overnight from a frozen stock and subcultured on to fresh CAB plates for 4 h. The bacteria were washed from the plates with PBS and washed three times with PBS/1 % BSA. The bacterial pellet from 500 ml cell suspension (half a plate of bacterial growth per 500 ml) was resuspended in 1 ml serum. The mixture was rotated for 90 min at 4 uC. The cells were spun and washed twice with PBS/1 % BSA and resuspended in 1 ml solubilization buffer (50 mM Tris, pH 7.8, 150 mM NaCl, 1 mM EDTA, 1 % Triton X-100, 0.2 % sodium deoxychloate, 0.1 % SDS). The mixture was incubated at 37 uC for 60 min followed by 60 min centrifugation at 14 100 g. Protein A/G UltraLink beads (50 ml) were added to the lysate and incubated overnight at 4 uC. The beads were washed five times with solubilization buffer followed by 1D gel electrophoresis. Duplicate immunoprecipitations were performed for each serum.
1D gel electrophoresis. To fractionate and solubilize the antigenic proteins, the preparations were electrophoresed on a 1D SDS-PAGE gel using a method based on that of Trinkle-Mulcahy et al. (2008) . Briefly, the proteins were eluted from the beads (50 ml) in one volume of 1 % SDS, boiling for 10 min followed by the addition of four volumes of water and vortexing. This was then spun and the resulting supernatant reduced using a Speed-Vac to 50 ml. The protein sample was reduced in 10 mM DTT (boiling for 2 min) followed by alkylation with 50 mM iodoacetamide (30 min, room temperature, in the dark). The sample was then mixed with SDS loading buffer and boiled for 5 min prior to separation on a 10 cm long, 1 mm thick 12 % SDS-PAGE mini-gel. The entire protein preparation was split in two to give a duplicate lane for each immunoprecipitation. Protein bands were visualized using SimplyBlue stain (Invitrogen). These gels were used for the MS analysis.
Sample digestion. The entire gel lane (duplicate samples and duplicate lanes) was cut into five slices. Gel slices were washed twice with 50 % acetonitrile in 25 mM ammonium bicarbonate for 15 min at room temperature. The gel pieces were dehydrated by incubating them with 50 ml 100 % acetonitrile for 20 min at room temperature. The gel pieces were dried using a Speed-Vac and rehydrated in 25 mM ammonium bicarbonate containing modified trypsin (Promega). Proteins were digested using trypsin for 16-20 h at 37 uC. The tryptic peptides were eluted by incubating the gel pieces with 30 ml 0.1 % formic acid/50 % acetonitrile for 20 min at room temperature. The supernatant containing tryptic peptides was collected. Additional peptides were extracted from gel pieces by incubation with a further 30 ml 0.1 % formic/50 % acetonitrile for 20 min at room temperature. The supernatant was then collected and combined with the first extraction. Finally, the extracted digested peptides were concentrated using a Speed-Vac and resuspended in 20 ml water.
Liquid chromatography-electrospray ionization-MS/MS. Samples were analysed by nano-liquid chromatography-electrospray ionization-MS/MS using an Ultimate 3000 nano-HPLC (Dionex), coupled to a QSTAR XL (Applied Biosystems,), a hybrid quadrupole time-of-flight instrument. The peptides were separated on a 75 mm, 25 cm, C18 pepmap column (Dionex-LC packing) maintained at 40 uC. The flow rate was set at 350 nl min 21 using a solvent gradient of 2-50 % B (90 % acetonitrile, 0.1 % formic acid; solvent A was 2 % acetonitrile, 0.1 % formic acid) over 30 min and 90 % B for 5 min under the control of Chromeleon software. The MS data were acquired using Information Data Acquisition with Analyst QS 1.1 software. A 1 s survey scan was acquired from m/z 400 to 1200 with the charge states 2-4. The two most intense product ions with an m/z of between 65 and 1200 amu were automatically selected for MS/MS. The electrospray voltage was set at 2300 V and the curtain gas at 8 arbitrary units.
Database analysis. The peak lists of MS/MS spectra from all the gel slices for any given sample were pooled and submitted to the Mascot Server (v2.2.04; Matrix Science), and analysed using the MS/MS Ions Search program. Protein identifications were made by searching against the National Center for Biotechnology Information nonredundant (NCBInr) database with the taxonomy set N. meningitidis (taxonomy code 487). Up to one missing trypsin cleavage was allowed, with fixed modification of carbamiodomethyl (C) and variable modification of oxidation (M). The search parameters were set with a peptide and MS/MS fragment tolerance of 1.2 and 0.6 Da respectively. MH 2 2+ and MH 3 3+ were selected as the precursor charge states. The Mascot data files were reanalysed using Scaffold (v2_03_01). This was used to validate MS/MS-based peptide and protein identifications based on a minimum of two identifying peptides. The identifications were assigned using the Protein Prophet algorithm (Nesvizhskii et al., 2003) . Data on the protein identification probability is included in the supplementary data.
Cloning and expression. NMB1870 [factor H-binding protein (fHBP)] and NMB0700 (IgA-specific serine endopeptidase) from L91543 were cloned and expressed using the Gateway cloning system (Invitrogen). Primers for the N and C terminals (Table 1) of the annotated ORFs from the N. meningitidis MC58 genome (http://cmr. tigr.org) were used to PCR amplify products from L91543 genomic DNA prepared according to Bjorvatn et al. (1984) . PCRs contained 10 mM Tris, pH 8.8, 25 mM KCl, 5 mM (NH4) 2 SO 4 , 2 mM MgSO 4 , 0.2 mM primers, 0.02 U Pwo DNA polymerase ml 21 (Roche) and 0.2 mM dNTPs. Cycle conditions were 94 uC for 5 min, followed by 35 cycles of 94 uC for 30 s, 58 uC for 30 s and 72 uC for 2 min, followed by 5 min at 72 uC. PCR products were first cloned into pDONR221 and transformed into Escherichia coli DH5a cells, according to the manufacturer's instructions. The correct constructs were identified by PCR and restriction digests. The resulting entry clone was then mixed with the pDEST vector and transformed into E. coli DH5a cells. The correct constructs were then transformed into E. coli BL21 cells. pET21b expressing fHBP, NMB1870-MC58, was kindly supplied by Chris Tang (Imperial College, London). Proteins were expressed by growing BL21 transformants to OD 600~0 .6 and inducing with 1 mM IPTG. Cells were incubated for 3 h, the cultures centrifuged, and the pellet lysed by resuspending in BugBuster H (Novagen) with 2 mg DNase ml 21 and 50 mg lysozyme ml 21 for 20 min. Lysates were centrifuged and the cleared supernatant applied to a previously equilibrated HisSelect (Sigma) column. The column was washed with 50 mM NaPO 4 , pH 8, 0.3 M NaCl, 5 mM imadazole and the proteins eluted with 50 mM NaPO 4 , pH 8, 0.3 M NaCl, 25 mM imadazole. Proteins were dialysed against 1000 volumes of PBS and quantified using a 2D Quant Kit (GE Healthcare).
Mouse immunizations. Recombinant proteins were used to generate serum according to Giuliani et al. (2006) . Briefly, female NIH mice (Harlan) were immunized subcutaneously on days 0, 21 and 35 with 20 mg protein each, initially with Freund's complete adjuvant and subsequently with Freund's incomplete adjuvant. Blood was collected on day 49 and the serum frozen. Animals were housed and cared for according to UK Home Office codes of practice and experiments were approved by the University of Surrey Ethics Committee.
Flow cytometry. N. meningitidis for flow cytometry were grown for 4 h on CAB. The bacteria were resuspended in PBS and adjusted to OD 600 1. A 20 ml volume of cells was centrifuged, and the pellet resuspended in 10 ml heat-denatured sera and incubated for 30 min at 37 uC. The cells were washed three times in 100 ml PBS plus 0.1 % Tween 20 (PBS-T) and resuspended in 100 ml 4 % paraformaldehyde for 18 h at 4 uC. Cells were washed three times in 100 ml PBS-T and resuspended in 20 ml anti-mouse IgG conjugated to FITC diluted 1 : 50 in PBS. Cells were incubated for 30 min at room temperature in the dark, washed three times in PBS-T and resuspended in 1 ml PBS. Fluorescence was measured with a BD FACSCanto flow cytometer recording 10 000 events and the data compared with samples containing either no cells, or cells stained with sera from mice immunized with fHBP, IgA-specific serine protease, OMV preparations or PBS alone. Data were analysed using WinMDI, recorded events were gated with reference to the control samples and the population statistics determined from triplicate experiments.
Western blot. The 1D SDS-PAGE gels were Western blotted onto PVDF membrane. Blots were incubated in PBS containing 10 % blocking reagent for 30 min at room temperature and then with mouse sera 1 : 500 for 1 h. Blots were washed three times for 10 min each with PBS-T and then incubated with 1 : 10 000 dilution of anti-mouse IgG conjugated with peroxidase for 30 min at room temperature followed by three 10 min washes with PBS-T. Blots Table 1 . PCR primers for NMB1870 (fHBP) and NMB0700 (IgA-specific serine peptidase) were developed with Lumi-Light (Roche) and exposed to X-ray film.
Serum bactericidal assay (SBA). SBAs were carried out according to Borrow & Carlone (2001) . Briefly, N. meningitidis, L91543 or MC58, grown overnight on CAB were inoculated into MuellerHinton broth to OD 600 0.1 and shaken at 35 uC for 4 h. Cultures were diluted to OD 600 0.1 and then diluted a further 1 : 5000; 10 ml was added to microtitre wells containing a 10 ml of a 1 : 4 dilution of baby rabbit complement (Serotech) and 20 ml of a twofold serial dilution of heat-denatured (56 uC for 30 min) sera. Plates were incubated for 1 h and samples plated onto CAB media. Each assay included control wells with either no sera, heat-inactivated complement or neither sera nor active complement. The SBA titre was the highest dilution showing ¢50 % killing compared with the control wells. SBA results for recombinant proteins were compared with sera from mice immunized with PBS alone, deoxycholate prepared OMVs (as a positive control for the SBA) and the known bactericidal antigen fHBP (assayed with N. meningitidis MC58, as a positive control for the recombinant protein production and immunization protocol).
RESULTS
CSIP-MS was performed with sera from 10 healthy individuals and a pooled commercial serum with two meningococcal strains as targets, N. meningitidis L91543 and MC58. All the subjects demonstrated a serum bactericidal activity ¢1 : 4 to both of the target strains ( Table 2 ). The strains were grown on plates, washed and suspended in the test serum. Cells were washed again and then lysed, under conditions that retained binding of antibody to target antigens, and antibody-antigen complexes were precipitated with Protein A/G beads. After reduction and alkylation, proteins were separated by 1D gel electrophoresis (Fig. 1) . The SimplyBlue-stained gel shows clearly the two predominant bands representing the IgG heavy and light antibody chains as well as a series of faint bands representing presumably the immunoprecipitated meningococcal proteins. No obvious differences were visible in the protein gels for the different subjects (data not shown).
In contrast to non-selective proteomics methods (Mendum et al., 2009) , only a limited number of proteins were detected (Table 3) by CSIP-MS with variation dependent on the subject and the target bacterial strain used for the immunoprecipitation (Table 4) . Of the proteins identified by CSIP-MS, 30 % were ribosomal proteins. Previous studies that identified ribosomal proteins attributed them to cytoplasmic contamination; however, in this study, with the chosen methodology, only surface-located proteins were likely to be isolated: surface locations of ribosomal proteins have been found for other bacteria (Bøhle et al., 2011; Severin et al., 2007) . The remainder of the proteins identified by CSIP-MS were mostly proteins predicted to be surface located and 62 % have already been investigated as potential meningococcal vaccine targets (Wright et al., 2002; Iagudaeva et al., 2010; Granoff, 2010; Gupta et al., 2010; Hung et al., 2013) . We have previously reported identifying many of these proteins by Western blot studies of whole meningococcal cell lysates (Mendum et al., 2009 ). However, in contrast to the previous study that detected a predominance of cytoplasmic proteins, the immunoprecipitated proteins revealed in the current study were skewed heavily towards surface proteins and previously investigated potential vaccine candidates.
All of the serum samples immunoprecipitated antigens from both strains except for sample 8 against MC58. The most frequently identified antigen was NMB0700 (IgA-specific serine peptidase), which was recognized by 18 of the 22 serum/cell combinations; however, most antigens were recognized by only a minority of the serum/cell combinations. It was notable that each serum sample gave a unique CSIP-MS profile, indicating the heterogeneity of immune responses against meningococci in healthy subjects. No meningococcal proteins were detected in the control immunoprecipitations without human serum.
Surface exposure of antigens
All the serum samples used for this study had a SBA titre ¢1 : 4; they all contained bactericidal antibodies that reacted against the target strains. To further investigate the relationship between protein surface exposure and serum bactericidal activity, we cloned and expressed two contrasting antigens: NMB0700 (IgA-specific serine peptidase), which was recognized by most sera in both strains (18 out of 22), and, fHBP (NMB1870), which was recognized only with MC58 as the target strain. Expressed protein was inoculated into mice and used to prepare antisera. The bactericidal titre of the generated antisera was measured against both strains. Flow cytometry was used to measure surface expression of each protein. Antisera to NMB0700 (IgA-specific serine peptidase) was shown to bind to the surface of both strains (Fig. 2) . However, despite its target being present on the surface, antibodies to IgA-serine peptidase were not bactericidal against L91543 or MC58.
The second protein investigated by flow cytometry was fHBP (NMB1870), which was detected by CSIP-MS with six of 11 sera when MC58 cells were used as the target, but by none of the serum samples when L91543 cells were the Table 4 . Meningococcal proteins identified from immunoprecipitations of L91543 and MC58 meningococcal strains with serum (samples 1-10 plus pooled serum, P) from healthy individuals Gene Protein L91543 target MC58 target Total 1 2 3 4 5 6 7 8 9 10 P 1 2 3 4 5 6 7 8 9 10 P NMB0124 Elongation factor-Tu 6 6 6 6 6 6 6 6 6 6 666 6 6 6 16 NMB0140 30S ribosomal protein S10 6 1 NMB0152 50S ribosomal protein L14 6 6 2 NMB0153 50S ribosomal protein L24 6 66 66 5 NMB0154 50S ribosomal protein L5 6 1 NMB0157 50S ribosomal protein L6 6 6 2 NMB0375 Adhesin MafA2 6 6 6 6 4 NMB0589 50S ribosomal protein L19 6 6 6 6 4 NMB0700 IgA-specific serine endopeptidase 6 6666666 6 6 666666 6 6 18 NMB0876 50S ribosomal protein L25/general stress protein Ctc 6 6 6 6 6 6 6 7 NMB1053 Class 5 outer membrane protein 6 6 2 NMB1429 PorA class 1 protein 6 6 6 3 NMB1460 ssDNA-binding protein 6 1 NMB1668 haemoglobin receptor 6 1 NMB1779 Haemagglutinin/haemolysin-related protein 6 6 6 6 6 5 NMB1870 Factor H-binding protein (fHBP) 6 6 666 6 6 NMB1969 Putative outer membrane peptidase 6 1 NMB1985 Adhesion and penetration protein (App1) 6 6 6 6 6 6 6 68 NMB1994 Putative adhesin/invasin (NadA) 6 1 NMB1998 Serine-type peptidase (Aus1) 6 6 6 666 6 6 8 NMB2039 Class 2 outer membrane protein 6 1 NMB2095 Putative adhesin component (ACP) 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 15 NMB2132 Neisserial heparin-binding antigen (NHBA) 6 6 2 target (Table 3 ). This protein is the major component of several vaccine formulations (Serruto et al., 2012) , thus its expression and recognition is of considerable interest. Several genetic variants of fHBP have been identified (Bambini et al., 2009) . To investigate whether sequence variability may be the cause of the lack of recognition in L91543, the L91543 gene sequence (data submitted to www.phbmlst.org/neisseria/fHbp) was compared with the NMB1870 gene sequence. Sequence analysis demonstrated very little sequence variation between the two genes, with the L91543 gene being classified into the same variant 1 group (Masignani et al., 2003) and the same subfamily B (Beernink & Granoff, 2009; Fletcher et al., 2004) as the MC58 sequence. L91543 fHBP was designated allele 807 (www.phbmlst.org/neisseria/fHbp). Flow cytometry (Fig.  3) analysis of anti-fHBP sera raised against either protein showed a positive interaction against MC58 cells, confirming that genetic variability was not the source of the lack of immunoreactivity of L91543 cells. In contrast, antibody raised against fHBP (MC58) did not show any surface binding to L91543 cells, whereas antibody raised against fHBP (L91543) bound less to the surface of L91543 cells than the antibody detected on the surface of MC58 cells (Fig. 3) . Taken together, the data demonstrated that fHBP was indeed present on the surface of both strains, but with a lower availability on L91543 cells compared with MC58 cells (Fig. 3 , compare a with b and c with d). Note, however, that the observed antibody binding of anti-fHBP to the surface of L91543 was not associated with any bactericidal activity (Fig. 3) , despite the same sera demonstrating a serum bactericidal titre ¢1 : 512 against MC58 cells. Surface expression and antibody binding is therefore not necessarily sufficient to cause bactericidal killing, and other factors, such as protein concentration or distribution of the protein on the surface of cells, are necessary to obtain successful killing.
DISCUSSION
We have demonstrated that CSIP-MS is able to sensitively detect and identify surface proteins of the meningococcus. Unlike traditional screening techniques such as Western blotting, CSIP-MS is capable of detecting conformational protein epitopes that are likely to be denatured during SDS-PAGE. The method is also highly selective for surfacelocated antigens, which are more likely to be targets of natural immunity. Not only were proteins detected by CSIP-MS shown to be predominantly surface located, but the CSIP-MS profile included many previously characterized vaccine candidate antigens that are components of new meningococcal vaccines. Although the detected proteins were diverse in function, a predominant family detected by CSIP-MS was the serine peptidases, including IgA-specific serine peptidase (NMB0700), MspA/Aus1 (NMB1998) (Turner et al., 2006; van Ulsen et al., 2006) and App1 (NMB1985) (Serruto et al., 2003) (Table 4) . MspA is an immunogenic autotransporter protein that mediates adhesion of N. meningitidis to epithelial and endothelial cells (Turner et al., 2006) . Antisera raised against MspA from the homologous strain (MC58) has previously been found to be bactericidal against the meningococcus (Turner et al., 2006) , highlighting the antigen as a potential vaccine candidate and the value of CSIP-MS for detection of potential vaccine candidate antigens. However, expression of MspA was also found to be strain variable (Turner et al., 2006; van Ulsen et al., 2006) and whereas one study detected antibodies to MspA in six of six convalescent sera (Turner et al., 2006) , another study (van Ulsen et al., 2006) failed to detect antibodies in any of 14 tested convalescent sera or sera from four healthy subject. In our study, sera from two of 11 subjects immunoprecipitated MspA from strain L91543, whereas six of 11 sera immunoprecipitated MspA from MC58 cells. The higher rate of positivity with MC58 could either reflect higher levels of MspA expression in the test strains or a higher rate of exposure of healthy subjects to the antigen present in MC58. Turner et al. (2006) observed greater anti-MspA reactivity on a Western blot with sera from patients infected with B strains.
Another vaccine candidate that was detected by CSIP-MS was NadA (NMB1994), although it was only precipitated by one of the pooled sera with L91543. NadA is known to be involved with host cell interactions and has a similar structure to other adhesins, such as YadA. Antibodies to NadA are strongly SBA-positive against homologous strains . However, the nadA gene can be found in only 50 % of meningococcal isolates and is more frequently associated with strains that belong to hypervirulent clusters (Comanducci et al., 2002 . The sequence is well conserved and five variants (Muzzi et al., 2013) have been identified: ET-37 strains, including L91543, encode allele 2, whereas MC58, an ET-5 strain, encodes allele 1. The low level of reactivity with subject sera is thereby likely due to lack of surface expression of this antigen in the selected test target strains. It has, however, been reported that this observed low expression may be the result of the in vitro growth conditions of the target strains (Fagnocchi et al., 2013) .
Neisserial heparin-binding antigen (NHBA; NMB2132), also termed genome-derived neisserial antigen (GNA2132), was also detected by CSIP-MS in sera from two subjects. This antigen is a surface-expressed lipoprotein (Serruto et al., 2010) that was first identified by reverse vaccinology (Pizza et al., 2000) and was detected in most disease-causing B strains investigated, but was associated with extensive antigenic variation with 14 allelic variants (Bambini et al., 2009) . Inoculation of mice with NHBA generated anti-GNA2132 antibodies that are positive in the SBA assay, the C3b deposition assay and the infant rat passive protection assay (Giuliani et al., 2006; Pizza et al., 2000; Welsch et al., 2003) . Serruto et al. (2010) have shown that vaccination with recombinant NHBA induces bactericidal antibodies in humans, which correlated with the level of expression of the antigen in target strains. Our finding that the protein was immunoprecipitated by sera in only two of our healthy subjects was due presumably to variability of allele and expression of the target antigen.
fHBP, which is a key component of two of the newgeneration serogroup B meningococcal vaccines (Fletcher et al., 2004; Masignani et al., 2003) , was also detected by CSIP-MS. However, this antigen showed a very distinctive pattern in being immunoprecipitated by the human serum samples with only the MC58 target strain, despite the gene being present and expressed in equal amounts in both strains as shown by Western blotting (Fig. 4) . Although this antigen is associated with significant levels of antigen diversity (Bambini et al., 2009; Serruto et al., 2012) , variability of the antigen was not the cause of the lack of detection in L91543 cells as antibody raised against the L91543 variant showed a higher level of binding to the surface of MC58 cells than to the surface of L91543 cells. The explanation appears to be that, although present and expressed, fHBP was present on the surface of L91543 cells, but was less available than with MC58 cells (Fig. 3) . Also, although antibody to the L91543 variant cells bound to the surface of L91543 cells, this level of antibody binding was not bactericidal. These results indicate that the presence or even expression of fHBP in target cells may not be sufficient to make it a target of protective immunity, potentially reducing the effectiveness of this antigen as a vaccine component. Similarly, Koeberling et al. (2011) described the requirement for a 'critical threshold' of expression of fHBP in order to elicit a positive SBA. Several adhesins were detected by CSIP-MS, including NMB2095, MafA2 (NMB0375) and the haemagglutinin/ haemolysis-related protein NMB1779. NMB2095 was immunoprecipitated in 10 of 11 serum samples with L91543 and five of 11 serum samples with MC58, making it one of the most frequently detected antigens in this study. This adhesin complex protein is highly conserved among the meningococci, and antisera elicits a positive SBA with homologous (MC58) and heterologous strains (Hung et al., 2013) . As with fHBP, detection of NMB1779 was also observed to be strain-specific.
Proteins that are predicted to be cytoplasmic were identified. Elongation factor (EF)-Tu (NMB0124) was detected by CSIP-MS in 16 of the 22 sera/cell combinations. EF-Tu is considered generally to be a cytoplasmic protein, but it has been reported previously to be surface associated (Kolberg et al., 2008) in ethanol-treated meningococcal cells using both anti-pneumococcal EF-Tu polyclonal rabbit serum and a mAb. However, EF-Tu has also been demonstrated to be immunogenic in the meningococcus as well as other bacteria (Mendum et al., 2009; Vytvytska et al., 2002) . Several ribosomal proteins were also immunoprecipitated by a minority of subject sera. These proteins have been reported previously to be located on the cell surface and to be immunogenic (Severin et al., 2007; Bøhle et al., 2011; Mendum et al., 2009 ). All of the ribosomal proteins detected by CSIP-MS showed strain specificity. In comparison with meningococcal OMV proteomic studies (Mendum et al., 2009; Vipond et al., 2006; Vaughan et al., 2006) , the range of predicted cytoplasmic proteins detected by CSIP-MS was restricted greatly and did not include the commonly observed proteins (e.g. DnaK, enolase, GroEL), demonstrating the selectivity of CSIP for detecting cell surface antigens.
Additional antigens detected by CSIP included classic outer membrane proteins, such as those of class 1 (PorA), class 2 (PorB) and class 5 (Opc). However, they were immunoprecipitated by only a small minority of serum samples, presumably due to the well-known antigenic variation of these proteins (Bart et al., 1999) .
One of the most striking results of this study was the variable CSIP-MS profile obtained with sera from healthy subjects that all had a SBA titre ¢1 : 4 against the target strains. The pattern of reactivity was very variable with no two subjects giving the same spectrum of antigen detection. This variability is likely to be a consequence of exposure, via carriage, to diverse neisserial strains circulating in communities. Another striking feature of the analysis was the finding that serum sample 8 did not immunoprecipitate any proteins with strain MC58 despite a SBA titre ¢1 : 512 against this strain. The results suggest that the SBA antibodies were targeted at non-protein moieties, such as lipopolysaccharide or capsular polysaccharide; such responses against serogroup B polysaccharide have been reported by others (Jordens et al., 2004) .
Overall, the results indicate that natural immunity is likely to be associated with recognition of a variety of antigens in different individuals -a conclusion that has significant implications for vaccine design and implementation.
CONCLUSIONS
CSIP-MS is a powerful technique when applied here for the first time to the meningococcus in that it was able to probe the surface of bacterial cells to identify antigens that may be potential candidate vaccine components, as well as investigating the correlates of protective immunity in individual subjects. The results demonstrate clearly the diversity in the immune response of healthy individuals to different meningococcal strains, the natural acquisition of known antigens and the strain-specific availability of antigens.
